You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 102 No. 6, June 1984 TABLE OF CONTENTS
  Archives
  •  Online Features
  LABORATORY SCIENCES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Xerophthalmia With Retinol, Tretinoin, and Etretinate

Diane L. Hatchell, PhD; Mary Faculjak; Diana Kubicek

Arch Ophthalmol. 1984;102(6):926-927.


Abstract

• Topical retinol, tretinoin (all-transretinoic acid) and etretinate (a synthetic retinoid) were used in rabbits to treat experimental xerophthalmia due to vitamin A deficiency. Both 0.2% retinol and 0.1% and 0.2% tretinoin effectively reversed abnormal corneal epithelial keratinization within one to two days and restored corneal clarity within two to four days following topical application three times per day. Etretinate was ineffective in the concentration used (0.2%). In addition, application of tretinoin to one eye effectively reversed xerophthalmic changes in the other eye. Retinol did not have an effect on the other eye.



Author Affiliations

From the Departments of Ophthalmology (Dr Hatchell and Mesdames Faculjak and Kubicek) and Physiology (Dr Hatchell), Medical College of Wisconsin, and the Research Service, Wood Veterans Administration Medical Center (Dr Hatchell), Milwaukee. Dr Hatchell is a Research to Prevent Blindness Inc, William and Mary Greve International Research Scholar and is now at the Duke University Eye Center, and the Durham Veterans Administration Medical Center, Durham, NC.


Footnotes

Accepted for publication Aug 29, 1983.

Reprint requests to Duke University Eye Center, Box 3802, Durham, NC 27710 (Dr Hatchell).

This study was supported in part by research grant EY01436 and Ophthalmic Research Center grant EY01931 from the National Eye Institute, by an unrestricted grant from Research to Prevent Blindness, Inc, New York City, and by VA Medical Research funds.

Etretinate was provided by Hoffmann-La Roche, Inc.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1984 American Medical Association. All Rights Reserved.